Clinical Trials

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Do you or your child have a platelet, bleeding, or white blood cell disorder? This study is looking at people who have platelet or other blood disorders. The researchers will use a blood sample to look for problems with platelets and a possible genetic cause in the participant’s DNA or RNA. To participate in this study, you must be a child or adult who either is healthy or has a platelet disorder, coagulation disorder, or white blood cell disorder. This study is located in New York, New York.

Are you an adult willing to give blood samples? This study investigates ways to prevent blood clotting in people with sickle cell disease. In this population, blood clotting is the most common cause of vascular death after heart attack and stroke. Scientists are studying the blood of people with sickle cell disease and comparing it with the blood of people without sickle cell disease over 2 years. To participate in this study, you must be between the ages of 18 and 80 years old and willing to participate for up to 2 years. This study takes place in Bethesda, Maryland.

Are you an adult who does not have high blood pressure and is interested in research? This study will investigate how the brain regulates the body’s response to stress and how infection with HIV or pre-hypertension affects regulation. Your heart and brain activity will be measured while you are at rest, during a mentally stressful task, and while you feel angry. The study will also test whether a breathing exercise improves regulation. People with and without HIV and pre-hypertension will be included. To participate in this study, you must be between 21 and 65 years old and not have high blood pressure. This study is located in Miami, Florida.

Do you have overweight? Circadian rhythm disorders can cause overweight and obesity. This study is examining how not getting enough sleep causes these complications. To participate in this study, you must be between the ages of 20 and 40 and have overweight but not obesity. This study is located in New York, New York.

Are you a healthy adult who regularly sleeps for 6.5 or fewer hours? This study is examining whether getting enough sleep can lower your risk of high blood pressure. To participate in this study, you must be between 18 and 65 years old, regularly sleep for 6.5 or fewer hours, and be able to adjust your sleep schedule for the study. This study is located in Rochester, Minnesota.

The study is designed to assess the usability of a novel CPAP human interface compared to a traditional nasal mask. Human subjects will interact with two different CPAP interfaces including a traditional CPAP mask and the 2nd generation DreamPort-Eclipse. Subjects will be requested to put on each of the different CPAP interface options a total of three times for a total of 6 trials. The order of device will be randomized.

The purpose of this research study is to see if obstructive sleep apnea (OSA) is associated with abnormalities in fat metabolism. Through this research study, the Investigator will evaluate how fat is metabolized in people with and without sleep apnea, what substances the fat tissue releases, and how these substances might change the way the body uses energy and sugar.

This research study is designed to learn, first, whether two anesthetics have different effects on collapse seen within the upper airway during sleep endoscopy. A second purpose is to learn whether collapse at several levels of the upper airway is associated with obstructive sleep apnea that persists after adenotonsillectomy, the surgery that removes the tonsils and adenoids.

This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions by improving endothelial cholesterol metabolism and trafficking in OSA (Aim 2).